Table 1.
| Characteristics | NSCLC (n=64) | SC (n=51) | CRC (n=38) | ||
|---|---|---|---|---|---|
| no. (%) | no. (%) | no. (%) | |||
| Mean age, years (range) | 62.0 (29-89) | 62.0 (31-85) | 60.5 (42-78) | ||
| Gender | |||||
| Male | 49 (76.6) | 41 (80.4) | 23 (60.5) | ||
| Female | 15 (23.4) | 10 (19.6) | 15 (39.5) | ||
| Stage | |||||
| IIIB | 5 (7.8) | 0 | 0 | ||
| IV | 59 (92.2) | 51 (100) | 38 (100) | ||
| Histology | |||||
| Adenocarcinoma | 30 (46.9) | 51 (100) | 38 (100) | ||
| Well or moderately differentiated | NA | 22 (43.1) | 28 (73.7) | ||
| Poorly differentiated | NA | 25 (49.0) | 10 (26.3) | ||
| Unknown | 0 | 4(7.8) | 0 | ||
| Squamous cell carcinoma | 23 (35.9) | 0 | 0 | ||
| Large cell carcinoma | 2 (3.1) | 0 | 0 | ||
| Unclassifiable | 9 (14.1) | 0 | 0 | ||
| Measurable target lesions | |||||
| Lungs | 63 (98.4) | 3 (5.9) | 9 (23.7) | ||
| Lymph nodes | 33 (51.6) | 28 (54.9) | 10 (26.3) | ||
| Liver | 9 (14.1) | 30 (58.8) | 30 (78.9) | ||
| Adrenal glands | 3 (4.7) | 0 | 0 | ||
| Bones | 3 (4.7) | 0 | 1 (2.6) | ||
| Pancreas | 1 (1.6) | 2 (3.9) | 1 (2.6) | ||
| Peritoneum | 0 | 1 (2.0) | 4 (10.5%) | ||
| Ovary | 0 | 0 | 1 (2.6) | ||
| First-line chemotherapy | |||||
| Taxane +/- platinum | 27 (42.2) | 7 (13.7) | 0 | ||
| Gemcitabine +/- platinum | 14 (21.9) | 0 | 0 | ||
| Irinotecan +/- platinum | 7 (10.9) | 0 | 0 | ||
| Pemetrexed +/- platinum | 6 (9.4) | 0 | 0 | ||
| Etoposide +/- platinum | 4 (6.2) | 0 | 0 | ||
| EGFR-TKI (gefitinib or erlotinib) | 6 (9.4) | 0 | 0 | ||
| FOLFOX | 0 | 24 (47.1) | 33 (86.8) | ||
| FOLFIRI | 0 | 2 (3.9) | 5 (13.2) | ||
| TS-1 or capecitabine +/- cisplatin | 0 | 13 (25.5) | 0 | ||
| 5-fluorouracil + cisplatin | 0 | 2 (3.9) | 0 | ||
| Docetaxel + oxaliplatin + TS-1 | 0 | 6 (11.8) | 0 |
Abbreviations: NSCLC, non-small cell lung cancer; GC, gastric cancer; CRC, colorectal cancer; NA, not available; EGFR-TKI, epidermal growth factor receptor inhibitor; FOLFOX, oxaliplatin plus 5-fluououracil/leucovorin; FOLFIRI, Irinotecan plus 5-fluorouracil/leucovorin.